According to our signature analysis, the results suggest that patients with a high infiltration level of CD68+ cells and Foxp3+ cells in tumor tissues are likely to benefit from neoadjuvant mono-immunotherapy, and patients with hyperactivated EGFR signaling are potential non-responders to neoadjuvant immunochemotherapy. Here, CD68 is linked to neoplasm.